Perspective and Directions for Future Developments on Ether Lipids
Publisher
Springer New York
Reference87 articles.
1. Adibhatla R. M., Hatcher J. F., and Dempsey R. J. (2006). Lipids and lipidomics in brain injury and diseases. AAPS J. 8:E314–E321.
2. Alcon S., Morales S., Camello P. J., and Pozo M. J. (2002). Contribution of different phospholipases and arachidonic acid metabolites in the response of gallbladder smooth muscle to cholecystokinin. Biochem. Pharmacol. 64:1157–1167.
3. Andresen T. L. and Jorgensen K. (2005). Synthesis and membrane behavior of a new class of unnatural phospholipid analogs useful as phospholipase A2 degradable liposomal drug carriers. Biochim. Biophys. Acta Biomembr. 1669:1–7.
4. Bae K., Longobardi L., Karasawa K., Malone B., Inoue T., Aoki J., Arai H., Inoue K., and Lee T. (2000). Platelet-activating factor (PAF)-dependent transacetylase and its relationship with PAF acetylhydrolases. J. Biol. Chem. 275:26704–26709.
5. Bernatchez P. N., Tremblay F., Rollin S., Neagoe P. E., and Sirois M. G. (2003). Sphingosine 1-phosphate effect on endothelial cell PAF synthesis: Role in cellular migration. J. Cell. Biochem. 90:719–731.